David Erritzoe
Clinical Associate Professor in Psychopharmacology
Data updated
Research Footprint
David Erritzoe appears in 84 tracked papers (2011–2026), most studied alongside Psilocybin, MDMA and Placebo, across Depressive Disorders, Neuroimaging & Brain Measures and Anxiety Disorders.
Most-cited paper: Trial of Psilocybin versus Escitalopram for Depression (1334 citations).
Frequent co-authors: Robin Carhart-Harris, David Nutt and Leor Roseman.
Publication Landscape
How the 84 papers Blossom tracks for David Erritzoe line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has David Erritzoe's publishing grown?
SourcedTracked papers by publication year; 1 earlier paper published before 2012. Click a year for the running total.
Don't read as total output: only the 84 of 84 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does David Erritzoe publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does David Erritzoe publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
David Erritzoe is a Danish-born psychiatrist and researcher based at Imperial College London. He serves as the Clinical Associate Professor in Psychopharmacology and the Head of the Centre for Psychedelic Research. He also directs the CIPPRes Clinic, focusing on the clinical application of psychedelics in psychiatry. His research utilizes neuroimaging (PET, MRI, EEG) to explore the neurobiology of mental illness and addiction.
Key Impact
Head of the Centre for Psychedelic Research at Imperial College London and director of the CIPPRes Clinic.
Collaboration Network
90 collaborators· click a node to visit their profile
Full network →Collaboration Network
See David Erritzoe's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations David Erritzoe is associated with.